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Abstract About 1 in 10 postmenopausal UK women are currently prescribed oral 
bisphosphonates, but there are concerns about their adverse effects. Osteonecrosis of the jaw 
is a recognised uncommon but important side effect of intravenous bisphosphonates, but 
epidemiological evidence on risk of osteonecrosis of the jaw associated with oral 
bisphosphonate use is less conclusive. 
The incidence of hospital admission with osteonecrosis of the jaw was examined among 
521,695 Million Women Study participants, aged 64.7 at baseline. Cox proportional hazards 
regression was used to estimate adjusted relative risks (RRs) and 95% confidence intervals 
(CIs) associated with use of oral bisphosphonates in postmenopausal women followed-up by 
record-linkage to National Health Service hospital admission databases. 
During mean follow-up of 8.2 years per woman, 100 women were admitted to hospital with 
first recorded osteonecrosis of the jaw, at mean age 72.4 years. Almost a third (29/100) of the 
cases had ever-used oral bisphosphonates. Ever-users had a six-fold increased risk of hospital 
admission for osteonecrosis of the jaw, when compared with never-users (adjusted RR=6.09, 
95% CI 3.83-9.66; p<0.0001). The relative risk for osteonecrosis of the jaw in never-users of 
oral bisphosphonates was increased in women with prior cancer (RR=3.40, 2.22-5.22, 
p<0.0001). The estimated absolute risk of hospital admission for osteonecrosis of the jaw over 
a 5-year period from age 70 to 74 was 0.09 per 1000 in never-users without prior cancer and 
0.69 per 1000 in ever-users of oral bisphosphonates. 
In this UK population of postmenopausal women, use of oral bisphosphonates was associated 
with a 6-fold increased risk of hospital admission with osteonecrosis of the jaw, accounting 
for around one-third of cases, with an excess risk of about 0.6/1000 users over 5 years.  
 




Since 2003, oral bisphosphonates have been recommended in the UK as first-line treatment for 
osteoporosis, following publications of the adverse effects of menopausal hormone therapy.    
Prescriptions for oral bisphosphonates have increased greatly since then, with some decline 
since about 2010 (Fig 1),[1] such that about 1 in 10 postmenopausal women in the UK [2, 3]  




Figure 1. Prescriptions for oral bisphosphonates and for menopausal hormone therapy 





Oral bisphosphonates are effective at reducing the risk of osteoporotic fracture, [6, 7] but there 
has been concern about their side effects, including increased risks of osteonecrosis of the jaw, 
atypical femoral fracture and atrial fibrillation.[8] 
Reliable population-based estimates of incidence of osteonecrosis of the jaw are lacking.[9-11]  
It is well-established that people given intravenous bisphosphonates as part of treatment for 
cancers such as breast cancer and multiple myeloma are at an increased risk of osteonecrosis 
of the jaw [12-16]; estimated prevalence is around 7-12% (depending on cancer and 
bisphosphonate types), with one study finding that the cumulative hazard of osteonecrosis of 
the jaw increases with duration of exposure to intravenous bisphosphonates by around 1% risk 
with 12 months treatment with intravenous bisphosphonates, around 3% with 24 months 
treatment, 6% with 36 months treatment, and around 13% with 48 months treatment, [16] and 
other studies showing similar increases in incidence with increasing duration of treatment. [12, 
14] In people taking oral bisphosphonates, however, there is uncertainty about the magnitude 
of any excess risk; recent epidemiological evidence has been limited by the lack of large scale 
medium-term to long-term prospective studies for this rare condition. Estimates of 
osteonecrosis of the jaw incidence in people taking oral bisphosphonates for osteoporosis or 
Paget’s disease have ranged between 1 in 10,000 and  <1 in 100,000 patient-treatment years 
[9, 17]; cumulative incidence of osteonecrosis of the jaw has been reported to rise with duration 
of oral bisphosphonate use in osteoporotic patients. [18] 
Using data from a large UK prospective cohort with virtually complete follow-up through 
routinely-collected national health databases, we report on the risk of hospital admission with 
osteonecrosis of the jaw in postmenopausal women by their use of oral bisphosphonates, 




2. Materials and Methods 
2.1 Study design, data collection and follow-up  
The Million Women Study is a prospective cohort study of 1.3 million women, recruited in 
England and Scotland from 1996-2001 through UK National Health Service (NHS) Breast 
Screening Programme mammography centres. At recruitment, women completed a 
questionnaire on socio-demographic, reproductive, medical and lifestyle factors, including 
medication use. The cohort is re-surveyed approximately every three to five years. The study 
design and methods are described in detail elsewhere; [19]  study questionnaires, as well as 
information on data and access policies, can be viewed online at 
http://www.millionwomenstudy.org.   
Electronic record linkage, using unique NHS identification numbers and date of birth as 
identifiers, links study participants to NHS records for follow-up of deaths, cancer registrations, 
emigration and hospital admissions.  Linked data for England are provided by NHS Digital, 
and for Scotland by NHS National Services Scotland, with diagnoses and procedures coded 
using, respectively, the World Health Organization’s International Classification of Diseases, 
10th revision (ICD-10) and the NHS OPCS-4 Classification of Interventions and Procedures. 
The hospital admissions databases (Hospital Episode Statistics (HES) in England and Scottish 
Morbidity Records in Scotland) include information on inpatient stays (i.e. overnight) and day-
case admissions; data are provided on hospital admission and discharge dates, and on diagnoses 
and procedures relating to the admission.  All participants gave written consent to follow-up, 
at recruitment. Ethical approval was granted by the Oxford and Anglia Multi-Centre Research 
Ethics Committee (MREC 97/001).  
 
2.2 Exposure variables 
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2.2.1 Oral bisphosphonate use  
Specific questions about use of oral bisphosphonates were asked for the first time 8 years after 
recruitment (in 2006-2007), which is the baseline for the analyses reported here.  Women were 
asked if they had ever taken alendronate (Fosamax), risedronate (Actonel), or etidronate 
(Didronel) and could answer ‘never’, ‘previously’, or ‘currently’ via a tick box. For analysis, 
women were classed as never or ever users of any of the named oral bisphosphonates.  
  
To assess the reliability of self-reported data, study participants were linked to data on 
prescriptions in primary care in the Clinical Practice Research Datalink (CPRD) in England, 
which covers about an 8% sample of the UK population,[20]    and in Scotland to data from 
the Prescribing Information System (PIS).[21] Among 28,762 women in England with a 
CPRD record, 93.6% of the 2761 study participants who in 2010-11 reported ever-use of oral 
bisphosphonate also had a prescription for the drug, and 97.0% of the 25,217 who reported 
never using bisphosphonate had no prescription for it. Among 38,095 women in Scotland, 
90.5% of the 3489 study participants who in 2010-11 reported ever-use of oral 
bisphosphonate also had a prescription for the drug, and 98.1% of the 33,951 who reported 
never using bisphosphonate had no prescription for it.  
2.3 Outcomes  
During the follow-up period, there was no specific ICD-10 code in the UK for osteonecrosis 
of the jaw.  ICD-10 codes K10.2 and M87.1 have been considered appropriate for identifying 
osteonecrosis of the jaw in disease register validation studies in Sweden and Denmark.[22, 23]  
We included in the outcome: women with a first hospital admission with ICD-10 code K10.2 
(inflammatory conditions of jaw), as primary or other diagnosis; or women with a first 
admission with ICD-10 code M87.1 (osteonecrosis due to drugs), except where code M87.1 
was accompanied by an operation code for hip replacement, and no mention of a condition of 
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the jaw: we considered that such women were likely to have steroid-induced osteonecrosis of 
the hip. We refer throughout to the outcome defined for these analyses as osteonecrosis of the 
jaw.  Osteonecrosis of the jaw related to bisphosphonate use is sometimes known as 
bisphosphonate-related osteonecrosis of the jaw (BRONJ), or, to include osteonecrosis of the 
jaw related to use of other medications, such as Denosumab, as medication-related 
osteonecrosis of the jaw (MRONJ).  
2.4 Statistical analysis 
For the main analyses, women contributed person-years from the date they completed the 8-
year follow-up questionnaire which asked for the first time about oral bisphosphonate use, up 
to the date of hospital admission for osteonecrosis of the jaw, the date of death, or last date of 
follow-up (31 March 2017), whichever was soonest.   About 1% of participants (n=19 705) 
have been lost to follow-up [19] (largely through emigration or leaving the National Health 
Service) and are censored at the date when they were lost, contributing person-years until then. 
Women were classed as having or not having prior cancer, based on registration of any cancer 
(ICD10 C00 to D48, excluding C44) prior to their report on bisphosphonate use. A record of 
prior head and neck cancer (radiotherapy treatment for which is a known risk factor for jaw 
osteonecrosis) was an exclusion criterion for all analyses of bisphosphonate use, and for some 
analyses women with a history of any other cancer were also excluded.    
 
Cox regression models using attained age as the underlying time variable were used to estimate 
relative risks (RRs) and 95% confidence intervals (CIs) for osteonecrosis of the jaw.  Floated 
confidence intervals were used when there were more than two categories for a risk factor; this 
allows valid comparisons to be made between any two groups.[24]   Conventional confidence 
intervals were used for dichotomous risk factors, and are accordingly reported in the text. 
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Analyses were stratified by single year at completion of the baseline questionnaire (8-year re-
survey) and by single year of birth, and adjusted for the following variables: recruitment region 
(10 regions), deprivation (deprivation score in quintiles, using the area-based Townsend Index 
[25]), body mass index (BMI; <20, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9, ≥30 kg/m2), 
strenuous activity (activity that causes sweating or heavier breathing - never, 1-2, 3-5, 6-10, 
≥11 hours per week), other physical activity (e.g. walking, gardening, leisure activities - never, 
1-2, 3-5, 6-10, ≥11 hours per week), smoking status (not current, current), alcohol consumption 
(<3, 3-6, 7-14, ≥15 drinks per week), highest educational attainment (tertiary, secondary, 
technical, none - left at or after school leaving age, none - left before school leaving age or no 
schooling), menopausal hormone therapy use, (ever, never) and diabetes (yes, no).  Missing 
data (generally <2% for each variable) for the adjustment variables were included as a separate 
category.  Analyses were performed using Stata, version 13.[26] 
2.5 Other exposures 
In the analyses, information on the exposures of interest and on smoking, alcohol, weight, 
physical activity, use of menopausal hormone therapy (HT) and diabetes were those recorded 
at baseline (the Million Women Study 8-year re-survey).  For some variables, generally those 
which would not be expected to change during follow-up, we used information provided at 
recruitment: deprivation, education, recruitment region, year of birth, year of recruitment, 
height (to calculate body mass index, BMI), and use of oral contraceptives. 
 
Among never users of oral bisphosphonates without prior cancer, number of cases and person-
years of follow-up were used to calculate the rate of hospital admission with osteonecrosis of 
the jaw for women aged 70 over a 5-year period.  Rates among women in other exposure 
categories (use of oral bisphosphonates, prior cancer, or both) were estimated by multiplying 
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the rate among never users without prior cancer by the appropriate point estimate of relative 
risk. 
3. Results 
The 521,695 postmenopausal women included in these analyses were aged 64.7 (SD 4.9) years, 
on average at baseline.  Overall 12% (60,440) reported ever use of oral bisphosphonates. Table 
1 shows the baseline characteristics of women in the analysis by reported oral bisphosphonate 
status.  Ever-users of oral bisphosphonates were slightly older and less likely to smoke than 
never-users, and had slightly lower BMIs.  Ever-users were somewhat more likely to have had 




Table 1:  Baseline characteristics and follow-up for incident osteonecrosis of the jaw by oral 
bisphosphonate use at baseline in postmenopausal women in the Million Women Studya 
 
 Never used oral 
bisphosphonates 
Ever used oral 
bisphosphonates 
Characteristics at study baseline n=461,255 n=60,440 
   Mean age, years (SD) 64.4 (4.8) 66.8 (5.2) 
   Deprivation: lowest fifth (%)b 15.7 17.5 
   Mean height, cm (SD)b 162.6 (6.5) 161.7 (6.8) 
   Mean weight, kg (SD) 69.4 (12.7) 64.9 (12.6) 
   Mean BMI, kg/m2 (SD) 26.3 (4.7) 24.8 (4.7) 
   Mean alcohol, g/d (SD) 4.9 (6.5) 3.8 (6.0) 
   Current smoker (%) 8.7 7.6 
   Mean no. of children (SD)b 2.1 (1.2) 2.1 (1.3) 
   Ever users of menopausal hormones (%) 53.6 54.6 
   Ever users of oral contraceptives (%)b 62.1 52.1 
   History of any cancer (%) 15.5 18.5 
   Fracture in last 5 years 9.0 31.4 
   
Follow-up for osteonecrosis of the jaw incidence   
Person-years follow-up (in millions) 4.0 0.3 
   
Number of cases of osteonecrosis of the jaw   
   Total 71 29 
   Women without prior cancer 46 24 
   Women with prior cancer 25 5 
aWomen with missing values were excluded from calculations of means or percentages for 
that given variable. 




During a mean follow-up of 8.2 years per woman (4.3 million person-years in total), 100 
women had a first hospital admission with osteonecrosis of the jaw, at mean age 72.4 (89 
with code K10.2, and 11 with code M87.1). No women with osteonecrosis of the jaw had a 
history of head or neck cancer. Of the 100 women identified with osteonecrosis of the jaw, 29 
had used oral bisphosphonates (5 with, and 24 without, a history of cancer), and 71 had never 
used them (25 with a history of cancer and 46 without).  In women who had never used oral 
bisphosphonates, the mean age at first hospital admission for osteonecrosis of the jaw was 
71.0 (SD 5.0) years in those without prior cancer, and 73.6 (SD 5.8) years in those with prior 
cancer.  In women who had used oral bisphosphonates, the mean age at first admission for 
osteonecrosis of the jaw was 73.6 (SD 6.2) years in those without prior cancer and 73.2 (SD 
3.0) years in those who had prior cancer.    
 
Figure 2 shows adjusted relative risks for hospital admission with osteonecrosis of the jaw by 
oral bisphosphonate use, prior cancer and 6 other selected factors.  Relative risks were greatest 
for ever use of oral bisphosphonates (RR=6.09; 95% CI 3.83-9.66, p<0.0001), and for a history 
of cancer (RR=2.80; 95% CI 1.88-4.17, p<0.0001); none of the remaining factors, smoking, 
body mass index, height, deprivation or use of menopausal hormone therapy or oral 
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Figure 3 shows relative risks taking never-users of oral bisphosphonates with no history of 
cancer as the baseline; never-users of bisphosphonates with a history of cancer were 3-times 
more likely to be admitted to hospital with osteonecrosis of the jaw (RR 3.40; 95% CI 2.22-
5.22, p<0.0001; Figure 3); and ever-users of oral bisphosphonates with a history of cancer had 
a 10-fold risk of hospital admission with osteonecrosis of the jaw of 10.6 (95% CI 4.40-25.7, 
p<0.0001).  Among women with no prior cancer, ever users of oral bisphosphonates were over 
7-times more likely to have a hospital admission with osteonecrosis of the jaw than never users 
(adjusted RR 7.88; 95% CI 5.21-11.9, p<0.0001; Figure 3).  Of the 5 ever-users of oral 
bisphosphonates with prior cancer who developed osteonecrosis of the jaw, some, but not all, 
had a history of breast cancer, and none had a history of myeloma; of the 25 never users with 







In women who never used oral bisphosphonates and had no history of cancer, the hospital 
admission rate for the 5-year period from age 70 to 74 for osteonecrosis of the jaw was 0.09 
per 1000.  Corresponding rates were 0.69 per 1000 ever-users of oral bisphosphonates with 
no history of cancer, 0.30 per 1000 never users of oral bisphosphonates with prior cancer, and 
0.93 per 1000 women aged 70 over 5 years in ever-users with prior cancer.  
4. Discussion 
In this UK population-based prospective cohort study of 521,695 postmenopausal women aged 
about 65 years followed up for an average of 8.2 years, ever users of oral bisphosphonates had 
a 6-fold increased risk of hospital admission with osteonecrosis of the jaw compared with never 
users. In women who had ever used oral bisphosphonates and had never had cancer, the risk of 
hospital admission with osteonecrosis of the jaw was increased nearly 8-fold compared with 
never users of oral bisphosphonates.  The absolute risk of hospital admission with osteonecrosis 
of the jaw for women without prior cancer over the 5-year period from age 70 to 74 years was 
0.09 per 1000 in never users of oral bisphosphonates, and 0.69 per 1000 in oral bisphosphonate 
users.  The risk of hospital admission with osteonecrosis of the jaw was increased about 3-fold 
in never users of bisphosphonates with a history of cancer and about 10-fold in ever-users of 
bisphosphonates with a history of cancer. 
   
Intravenous bisphosphonates given mainly for treatment of cancer have consistently been 
associated with an increased risk of osteonecrosis of the jaw, with around 7-12% of those 
treated reported to be affected,[12-16] and some evidence for risk increasing with increasing 
duration of treatment. [12, 14, 16]  Risk of osteonecrosis of the jaw has also been linked to use 




Epidemiological evidence is less consistent with respect to risk of osteonecrosis of the jaw in 
users of oral bisphosphonates typically taken for prevention of osteoporotic fracture.  Some 
studies have reported no increase in risk associated with oral bisphosphonate use [27, 28] 
though most, including recent large-scale registry-based studies and a meta-analysis, [29-33] 
have reported increased risks in users of oral bisphosphonates, generally lower (2-5 fold 
relative risk) and possibly with a longer time to onset [34] than for intravenous bisphosphonate 
use.  After adjustment for potential confounding factors, the relative risk of hospital admission 
for osteonecrosis of the jaw in ever-users of oral bisphosphonates in this cohort was 6-fold 
overall and almost 8-fold in women with no history of cancer, with lower 95% confidence 
intervals of 4-5.  
 
Reports from UK clinical surveys [11, 35], several large register-based studies, [30-32, 36] and 
review articles [9, 17]  have estimated incidence rates of osteonecrosis of the jaw of between 
0.0001 and 0.04% per year (i.e. between 0.005-2.0 per 1000 over 5 years) in those treated with 
oral bisphosphonates for osteoporosis or Paget’s disease.   In this cohort, hospital admission 
rates were 0.69 per 1000 users over 5 years, but we have no data on incidence rates that include 
women not admitted to hospital. A survey of UK dental and oral clinicians estimated some 700 
cases of bisphosphonate-related osteonecrosis of the jaw annually in the UK; [11] and with 
some 7-8 million prescriptions annually (Fig 1),[1] this suggests an incidence rate of about 0.25 
per 1000 over 5 years (assuming an average of about 2 prescriptions annually per woman). 
 
In this study almost a third (29/100) of the hospital admissions for osteonecrosis of the jaw 
were associated with use of oral bisphosphonates, consistent with other estimates that between 
10% and 50% of all cases of osteonecrosis of the jaw may be related to use of oral 




The main strengths of this study are the large study population, with validated prospective 
recording of exposure to oral bisphosphonates and long-term, virtually complete follow-up 
through reliable nationwide health service registers. While use of intravenous bisphosphonates 
was not recorded on the analysis baseline (8-year re-survey) questionnaire, in this study the 
great majority (over 99%) of women reporting use of bisphosphonates for osteoporosis on later 
questionnaires were using oral preparations; and our analyses in women without prior cancer 
exclude the possibility of unrecorded use of intravenous bisphosphonates at oncology doses.  
Many cases of osteonecrosis of the jaw arise in the context of invasive dental treatment; the 
hospital admissions registers used include specialist dental hospitals. To our knowledge, this 
is the first population-based cohort (non-register) study, in the UK or elsewhere, to provide 
estimated incidence rates and relative risks for osteonecrosis of the jaw in relation to use of 
oral bisphosphonates, taking into account a wide range of potential demographic and lifestyle 
confounders. A limitation of the study is identification of osteonecrosis of the jaw using the 
available hospital record ICD-10 codes, which were not designed to capture this specific 
outcome. It is also possible that in recent years recognition of a potential link between 
bisphosphonate use and osteonecrosis of the jaw may have led to changes in the diagnosis 
and/or recording of osteonecrosis of the jaw in hospital data. The codes on which our outcome 
definition was based, for inflammatory conditions of the jaw (K10.2) and for osteonecrosis due 
to drugs (M87.1), have been used previously,[30] and validation against clinical records in 
Sweden and in Denmark [22, 23] suggested that these codes are acceptable for use in large 
epidemiological studies, although positive predictive values were relatively low.  The 
advantage of using all available data to specify the outcome has been noted previously [31]. A 
strength of the present study is the exclusion of about 10% of those with one of the above 
codes, whose detailed records suggested that code M87.1 was likely to reflect steroid-induced 
necrosis of the hip.  We also had information on prior cancer by site, and were able to confirm 
that no women in the analysis were identified with osteonecrosis of the jaw following head and 
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neck cancer, with possible radiotherapy to the jaw.  All cases of osteonecrosis of the jaw 
diagnosed through surgery in hospital should be included, as hospital data include day-case 
admissions; nevertheless they are likely to represent the more severe cases (and may not 
include more recently-recognised variants without bone exposure).  Hospital outpatient data in 
the UK do not contain full diagnostic coding and cannot be used to ascertain disease outcomes; 
and we do not have information on dental treatment in primary dental practice.  Overall 
incidence of osteonecrosis of the jaw in this population is likely to be underestimated.  
  
Even in this large cohort with 8 years’ follow-up, there were relatively few incident cases of 
osteonecrosis of the jaw. Since most bisphosphonate use was recent, our analyses were limited 
to a comparison between ever and never users of bisphosphonates. We therefore have little 
reliable data about whether the excess risks observed here persist many years after 
bisphosphonate use ceases or about the effects of different duration of use of oral 
bisphosphonates. 
 
The widespread use of oral bisphosphonates for prevention of osteoporotic fracture means that 
adverse effects, even if uncommon, may be of population health concern. Based on current 
guidelines for treatment of osteoporosis, it has been estimated that half of all post-menopausal 
women fulfil the criteria for pharmacological intervention.[37, 38] Prevalence of use of oral 
bisphosphonates among postmenopausal women in many high-income countries, including the 
UK, is estimated to be above 10%.  To limit the possibility of serious side effects, recent 
guidelines in the UK suggest that long-term bisphosphonate therapy in postmenopausal women 
should be reviewed after about 3-5 years and that a drug holiday should be considered in 





In conclusion, in this large UK prospective cohort of postmenopausal women, ever-users of 
oral bisphosphonates had a 6-8 times higher risk than never users of a hospital admission with 
diagnostic codes indicative of osteonecrosis of the jaw. The absolute excess incidence of 
hospital admission for osteonecrosis of the jaw over a 5-year period from age 70 to 74 was 0.6 
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